Paul B. Jacobsen
Associate Center Director
Division of Population Science

Professor (Courtesy)
Department of Psychology
University of South Florida

12902 Magnolia Drive
 Tampa, FL 33612-9416
Phone: (813) 745-3862
Fax: (813) 745-3906

Assistant: Christine Marsella

Curriculum Vitae

Other Links

Moffitt Behavioral Oncology Post-Doctoral Training Program

University of South Florida PhD Program in Clinical Psychology

Coping with Chemotherapy Intervention Material (Cancer Control Planet)


My research focuses on behavioral and psychosocial aspects of cancer and is conducted at the H. Lee Moffitt Cancer Center and Research Institute. The goal of this work is to demonstrate how an understanding of psychological principles can be used to reduce cancer-related morbidity and mortality.

Over the past few years, my colleagues and I have conducted a number of studies investigating the etiology and management of behavioral side effects of cancer treatment. With funding from the American Cancer Society and the National Cancer Institute, we demonstrated that a brief self-administered cognitive-behavioral intervention (stress management training) is effective in improving patients’ quality of life as they undergo cancer chemotherapy treatment. Based on these findings, we are currently evaluating a version of this intervention transcreated for Hispanic/Latina women receiving chemotherapy and are also developing a web-based version for English-speaking patients.

Much of my work has also focused on investigating fatigue, one of the most common and distressing symptoms experienced by cancer patients. Our research has led to the development of tools to measure fatigue, estimates of the prevalence and intensity of fatigue during and following completion of cancer treatment, and identification of clinical and psychological factors that explain individual differences in fatigue severity. We have recently begun developing an Internet-assisted cognitive-behavioral intervention designed for patients who are experiencing fatigue related to targeted oral cancer therapies.